Shanxi Zhendong Pharmaceutical Co., Ltd.
300158 · SZSE · China
zdjt.comFinancials as of FY2024 · latest on file
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
3.92BCNY754.09M · vs all stocks (USD)
Revenue (TTM)
2.10BCNY363.13M · vs all stocks (USD)
Profit Margin
-23.50%Beta
0.2450xvs all stocks
52-Week Change
-38.28%vs all stocks
Market Capitalization
3.92BCNY754.09M · vs all stocks (USD)
Enterprise Value
3.41BCNY658.38M · vs all stocks (USD)
Forward P/E
9.63xPrice to Sales (TTM)
1.87xPrice to Book (MRQ)
1.23xEnterprise to Revenue
1.62xEnterprise to EBITDA
-8.86xGross Margin
52.20%Profit Margin
-23.50%Operating Margin
-23.74%Return on Assets (TTM)
-7.17%Return on Equity (TTM)
-14.67%Revenue (TTM)
2.10BCNY363.13M · vs all stocks (USD)
Revenue per Share (TTM)
2.11CNYUpdated Nov 22, 2026Quarterly Revenue Growth
-42.40%Gross Profit (TTM)
1.01BCNY182.01M · vs all stocks (USD)
EBITDA (TTM)
-384.64MCNY-47.54M · vs all stocks (USD)
Net Income (TTM)
-493.79MCNY-60.21M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-41.35%Operating Cash Flow (TTM)
-183.23MCNY-60.77M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
44.18MCNY-30.09M · vs all stocks (USD)
5-Year Average Dividend Yield
1.08%vs all stocks
Payout Ratio
119.62%Minority Interest (Equity)
-37.37MCNYFY2024 · Dec 31, 2024Revenue
2.97BCNYFY2024 · Dec 31, 2024Cost of Goods Sold
1.56BCNYFY2024 · Dec 31, 2024Gross Profit
1.41BCNYFY2024 · Dec 31, 2024Operating Income
-338.83MCNY-50.79M · vs all stocks (USD)
Pre-tax Income
-1.32BCNYFY2024 · Dec 31, 2024Income Tax Expense
17.92MCNYFY2024 · Dec 31, 2024Net Income
-1.33BCNYFY2024 · Dec 31, 2024EBIT
-1.31BCNYFY2024 · Dec 31, 2024EBITDA (Income Statement)
-777.77MCNYFY2024 · Dec 31, 2024Research & Development
351.48MCNYFY2024 · Dec 31, 2024Selling, General & Administrative
1.01BCNYFY2024 · Dec 31, 2024Other Operating Expenses
30.85MCNYFY2024 · Dec 31, 2024Non-operating Interest Income
5.67MCNYFY2024 · Dec 31, 2024Non-operating Interest Expense
3.61MCNYFY2024 · Dec 31, 2024EPS (Basic)
-1.30CNYFY2024 · Dec 31, 2024EPS (Diluted)
-1.30CNYFY2024 · Dec 31, 2024Basic Shares Outstanding
1.02BSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
1.02BSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-1.33BCNYFY2024 · Dec 31, 2024Minority Interests (P&L)
4.38MCNYFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00CNYFY2024 · Dec 31, 2024Operating Cash Flow
-1.04BCNYFY2024 · Dec 31, 2024Free Cash Flow
-1.33BCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
558.02MCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-1.33BCNYFY2024 · Dec 31, 2024Other Non-cash Items
9.38MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
115.00MCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
173.23MCNYFY2024 · Dec 31, 2024Capital Expenditures
-290.71MCNYFY2024 · Dec 31, 2024Net Acquisitions
988.38KCNYFY2024 · Dec 31, 2024Purchase of Investments
-6.06BCNYFY2024 · Dec 31, 2024Sale of Investments
6.39BCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
39.51MCNYFY2024 · Dec 31, 2024Long-term Debt Issuance
38.11MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-53.35MCNYFY2024 · Dec 31, 2024Common Dividends Paid
-584.65KCNYFY2024 · Dec 31, 2024Other Financing Charges
-78.67MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
-94.49MCNYFY2024 · Dec 31, 2024Shares Outstanding
992.30MSharesUpdated Nov 22, 2026Float Shares
658.65MSharesUpdated Nov 22, 2026% Held by Insiders
41.17%vs all stocks
% Held by Institutions
0.13%vs all stocks
Total Cash (MRQ)
759.51MCNY108.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7650CNYUpdated Nov 22, 2026Total Debt (MRQ)
286.30MCNY33.49M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0912xCurrent Ratio (MRQ)
2.26xBook Value per Share (MRQ)
3.20CNYUpdated Nov 22, 2026Total Assets
4.98BCNY746.86M · vs all stocks (USD)
Total Current Assets
3.22BCNYFY2024 · Dec 31, 2024Total Liabilities
1.32BCNYFY2024 · Dec 31, 2024Total Non-current Assets
1.77BCNYFY2024 · Dec 31, 2024Total Non-current Liabilities
67.43MCNYFY2024 · Dec 31, 2024Total Current Liabilities
1.26BCNYFY2024 · Dec 31, 2024Cash
540.73MCNYFY2024 · Dec 31, 2024Cash Equivalents
43.86MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents
584.59MCNYFY2024 · Dec 31, 2024Other Short-term Investments
989.62MCNYFY2024 · Dec 31, 2024Accounts Receivable
519.55MCNYFY2024 · Dec 31, 2024Inventory
775.98MCNYFY2024 · Dec 31, 2024Accounts Payable
328.01MCNYFY2024 · Dec 31, 2024Short-term Debt
40.12MCNYFY2024 · Dec 31, 2024Other Current Liabilities
11.36MCNYFY2024 · Dec 31, 2024Long-term Debt
1.09MCNYFY2024 · Dec 31, 2024Common Stock (Book)
1.01BCNYFY2024 · Dec 31, 2024Retained Earnings
-1.39BCNYFY2024 · Dec 31, 2024Total Shareholders' Equity
3.66BCNY548.64M · vs all stocks (USD)
Treasury Stock
2.84MCNYFY2024 · Dec 31, 202452-Week Low
3.95CNYUpdated Nov 22, 202652-Week High
7.08CNYUpdated Nov 22, 202652-Week Change
-38.28%vs all stocks
Beta
0.2450xvs all stocks
50-Day MA
4.96CNYUpdated Nov 22, 2026200-Day MA
5.37CNYUpdated Nov 22, 2026Avg 10-Day Volume
9.62MSharesUpdated Nov 22, 2026Avg 30-Day Volume
10.38MSharesUpdated Nov 22, 2026Diluted EPS (TTM)
-0.4900CNYUpdated Nov 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Guizhou Bailing Group Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chongqing Pharscin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacific Biosciences of California, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytek Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk